Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CITADEL-204
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
- NCT03144674 ↗
- Completed
- Incyte Corporation
- Focused
We haven't built an HCP commentary report on CITADEL-204 (parsaclisib in relapsed or refractory marginal zone lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CITADEL-204 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Lymphoma
- Interventions
- Parsaclisib
- Arms
- Cohort 1- Closed to Further enrollment · Experimental
- Cohort 2 · Experimental
- Enrollment
- 110
- Primary outcomes
- Objective Response Rate (ORR) Based on Lugano Classification Criteria
- Sponsor
- Incyte Corporation
- Start
- Dec 18, 2017
- Primary completion
- Jan 15, 2021
- Results posted
- Yes
- Registry record
- NCT03144674 · updated Jul 11, 2025